- Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.
- Eli Lilly and Novo Nordisk both launched oral GLP-1 medications this year, marking a major competitive development in the market.
- Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.
Eli Lilly and Novo Nordisk have both developed anti-obesity drugs, intensifying competition in the weight loss market.
6 reports, 3 independent
Updated Aug 21
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 6
- Developments
- 9
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Eli Lilly and Novo Nordisk have both developed anti-obesity drugs, intensifying competition in the weight loss market.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Novo Nordisk strengthens its R&D pipeline in the fields of obesity and diabetes.Sub-event
- Eli Lilly's tirzepatide proved more effective than Novo Nordisk's semaglutide in the obesity drug market.Sub-event
- Novo Nordisk submitted a new dose for its obesity drug, driven by intensifying competition in the weight loss market.Sub-event
- Eli Lilly raised Zepbound prices in the U.K. and plans to follow price hikes across Europe, while Novo Nordisk received a drug price reduction letter amid Trump administration pressure.Sub-event
- Mounjaro's approval caused a decline in Trulicity sales, marking a specific development in the weight loss drug market.Sub-event
Lilly and Novo Nordisk have developed anti-obesity drugs, escalating market competition.1 source
Competition heats up as Lilly and Novo Nordisk face pricing pressures and MFN alignment discussions.1 source
- Novo Nordisk launched Wegovy in India amid rivalry with Eli Lilly.
Show 1 earlier step
- Citi reported optimism regarding Eli Lilly's growth as the two companies lead the obesity treatment market.
Keep exploring
Part of
Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.Also in this story
- Novo Nordisk and Eli Lilly are utilizing physician networks in Texas, including Carlos Campos, to promote their weight-loss drugs.
- UK MHRA approved Foundayo for commercialization, marking a significant market entry point in the global obesity drug competition.
- Bullish outlook for Eli Lilly due to strong sales momentum and durable patent coverage for its obesity treatment portfolio into the 2030s.
- Eli Lilly and Novo Nordisk are leading the weight management market, with plans to seek label expansion applications in Europe.
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
Novo Nordisk
Danish pharmaceutical company
Related events
- Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.
- Eli Lilly and Kailera Therapeutics are competing in the obesity treatment market.
- Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.
- Medicare has approved coverage for obesity drugs from Novo Nordisk and Eli Lilly.
- Eli Lilly and Novo Nordisk are facing scrutiny regarding their name-brand weight loss drugs due to findings during an FDA data review.
Coverage
Newest first; wire copies grouped- Motley FoolIs Beaten-Down Viking Therapeutics Stock a Buy on the Dip? Viking Therapeutics' stock recently tanked after reporting clinical trial results for an oral anti-obesity candidate. The healthcare company
- BenzingaNovo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2
- ZacksCan Wegovy & Ozempic Drive Another Strong Quarter for Novo Nordisk? Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II diabetes (T
- Motley Fool3 Reasons I Bought Novo Nordisk Stock Instead of Eli Lilly Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's GLP-1 drugs may
- Unknown outlet
- Unknown outlet